@TaxiBiotech TaxiBiotech

TaxiBiotech posts on X about $crnx, $dnli, $rzlt, $upb the most. They currently have [---] followers and [---] posts still getting attention that total [--] engagements in the last [--] hours.

Engagements: [--] #

[--] Week [-----] +21,770%
[--] Month [-----] +164%
[--] Months [------] -23%
[--] Year [-------] +409%

Mentions: [--] #

[--] Week [--] +160%
[--] Month [--] +18%
[--] Months [---] -6.90%
[--] Year [---] +288%

Followers: [---] #

[--] Week [---] +1.10%
[--] Month [---] +1.10%
[--] Months [---] +21%
[--] Year [---] +350%

CreatorRank: undefined #

Social Influence

Social category influence stocks 60% finance 10% cryptocurrencies 4% technology brands 4% exchanges 3% celebrities 2%

Social topic influence $crnx 4%, $dnli 4%, $rzlt 4%, $upb 4%, $18m 4%, $kymr 4%, kymera 4%, $prok 4%, prokidney 4%, data 4%

Top accounts mentioned or mentioned by @hermeslux @wassimlaroussi3 @yydsxjm @pharmdca @ohwhyamerica @at_truthmatters @biotech2k1

Top assets mentioned Crinetics Pharmaceuticals, Inc. (CRNX) Denali Therapeutics Inc. Common Stock (DNLI) Upstream Bio, Inc. (UPB) Kymera Therapeutics, Inc. (KYMR) Lexeo Therapeutics, Inc (LXEO) Biomea Fusion, Inc. (BMEA) Synthetify (SNY) Arvinas, Inc (ARVN) Pharvaris, B.V. (PHVS) Centessa Pharmaceuticals plc (CNTA) AltLayer (ALT) Maplebear Inc. (CART) Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) BridgeBio Pharma, Inc. Common Stock (BBIO) NovoCure Limited Ordinary Shares (NVCR) Pfizer, Inc. (PFE) uniQure N.V. (QURE) Fractyl Health, Inc. (GUTS) ImmunityBio, Inc. Common Stock (IBRX) C4 Therapeutics, Inc (CCCC) Dyne Therapeutics, Inc. (DYN) Pyxis Oncology, Inc. (PYXS) MBX Biosciences, Inc. (MBX) Marblex (MBX) Sanofi (SNY) Ventyx Biosciences, Inc. (VTYX) MAIA Biotechnology, Inc. (MAIA) Black Diamond Therapeutics Inc. (BDTX) Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Terns Pharmaceuticals, Inc. (TERN)

Top Social Posts

Top posts by engagements in the last [--] hours

"$CNTA Centessa Pharmaceuticals Cash: $349 M runway to mid-2027. net loss: $54.9M vs $42.6M Q3 [----] Pipeline: OX2R agonist program with ORX750 registrational program in Q1 [----] ORX489 to IND ORX142 initiation Q1 [----] 👉 https://www.globenewswire.com/news-release/2025/11/05/3181265/0/en/Centessa-Pharmaceuticals-Reports-Financial-Results-for-the-Third-Quarter-of-2025-and-Provides-Update-on-Potential-Best-in-Class-Orexin-Receptor-2-OX2R-Agonist-Program.html"
X Link 2025-11-06T15:47Z [---] followers, [---] engagements

"$BOLD Boundless Bio Cash: $117.6 M Runway: Through mid-2028. Q3 net loss: $13.9 M vs $16.5 M in Q324. Pipeline: Enrollment ongoing in BBI-355 / BBI-825 combination. BBI-940 (Kinesin degrader) IND planned H1 [----]. Next milestone: Initiation of first-in-human trial for BBI-940 in H1 [----] 👉 https://www.globenewswire.com/news-release/2025/11/05/3181282/0/en/Boundless-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html https://www.globenewswire.com/news-release/2025/11/05/3181282/0/en/Boundless-Bio-Reports-Third-Quarter-2025-Financial-Results-and-Business-Highlights.html"
X Link 2025-11-06T15:47Z [---] followers, [---] engagements

"I break down [--] Nasdaq biotech companies with cash runway to [----] and major catalysts coming in [--------] Tickers covered: $ALT $CART $DYNE $CRNX $ETON $DNLI $RZLT $LXEO $UPB $SYRE $RYTM $ACIU $NMB $BBIO $NVCR https://youtu.be/LL2ySHVDHIA https://youtu.be/LL2ySHVDHIA"
X Link 2025-11-17T15:21Z [---] followers, [---] engagements

"11_12_25 🗞🧬 Biotech Stock News. Daily Recap. English REZOLUTE $RZLT VALNEVA $VALN IMMATICS $IMTX ACIMMUNE $ACIU CORBUS $CRBP"
X Link 2025-12-11T16:23Z [---] followers, [---] engagements

"January_09_26 🗞🧬 Biotech Stock News. Daily Recap. English $KRYS Krystal Biotech $PDSB PDS Biotechnology $MDGL Madrigal Pharmaceuticals $PFE Pfizer $QURE uniQure $AQST Aquestive Therapeutics $LNA Leona Bio (antes Athira Pharma) MapLight Therapeutics (Privada) $ASND Ascendis Pharma. https://twitter.com/i/web/status/2009685509426016715 https://twitter.com/i/web/status/2009685509426016715"
X Link 2026-01-09T17:55Z [---] followers, [---] engagements

"01_29_26 Biotech Stock News . Daily Recap. #English $APRE $IMMP $SER $GUTS $PFSA #Shorts $XBI #trading #biotechnews #dailynews https://www.youtube.com/shorts/XAWOll0heF4 https://www.youtube.com/shorts/XAWOll0heF4"
X Link 2026-01-29T16:21Z [---] followers, [---] engagements

"Biotechs are so misunderstood. They invest hundreds of millions to save lives yet the world expects drugs for free💔 $HIMS And because of patents they only have [--] years to maximize returns. After that they go FREE. How much is health worth Is it time to reform patents"
X Link 2026-02-10T06:12Z [---] followers, [---] engagements

"Es ImmunityBio $IBRX la gran revolucin o puro humo 🧬 Analizamos a fondo la ciencia detrs de Anktiva sus resultados y competencia y si su CEO es realmente el "Elon Musk" de la biotecnologa. 🚀🧪 #ImmunityBio #Bolsa #Biotech #Inversiones https://www.youtube.com/watchv=8dH4updxzLU https://www.youtube.com/watchv=8dH4updxzLU"
X Link 2026-02-10T15:36Z [---] followers, [----] engagements

"Is ImmunityBio $IBRX the next big revolution or just hype Deep diving into the science behind Anktiva its 71% CR in bladder cancer other drugs in bladder cancer and if their CEO is the "Elon Musk" of biotech. 🚀🧪 #Biotech #StockMarket #Investing https://www.youtube.com/watchv=upF8w_ptfDc https://www.youtube.com/watchv=upF8w_ptfDc"
X Link 2026-02-10T15:38Z [---] followers, [---] engagements

"This news certainly hurts investment in the industry. But analyzing just the product there's a clear hurdle for mRNA flu vaccines in EUROPE: public preference. Most people still lean toward traditional FLU shots (even at 50% efficacy) over mRNA platforms. The backlash from the COVID-19 era has created a stigma that's hard to overcome when 'good enough' alternatives exist. In my circles annual flu shots are standard but COVID boosters are not. Until this generational mindset shifts it might be wiser to target diseases that lack competent therapies rather than disrupting what already works. Is"
X Link 2026-02-12T05:31Z [---] followers, [---] engagements

"@HermesLux Why not yesterday As they sell $STRC they Buy $BTC. I thought it was immediate"
X Link 2026-02-13T17:02Z [---] followers, [---] engagements

"$UPB es una oportunidad Los deberes del video de noticias de hoy: Reduccin significativa de ataques de asma. Pero la eficacia cae en las dosis a [--] semanas. Se cuestiona su ventaja competitiva frente a la competencia. Rally +300% YoY = venta por debajo de las expectativas. https://www.youtube.com/shorts/gOasQfKL4-U https://www.youtube.com/shorts/gOasQfKL4-U"
X Link 2026-02-11T18:38Z [---] followers, [---] engagements

"Is $UPB an opportunity Key takeaways from today's VIDEO news: Significant reduction in asthma attacks. However efficacy drops with 24-week dosing. Competitive advantage against peers is being questioned. +300% YoY rally = sell-off as results came in below expectations. https://www.youtube.com/shorts/T_d0rVuiHzs https://www.youtube.com/shorts/T_d0rVuiHzs"
X Link 2026-02-11T18:40Z [---] followers, [---] engagements

"@WassimLaroussi3 Joder qu bueno. Podas haber probado en la MLS 😇"
X Link 2026-02-14T21:40Z [---] followers, [--] engagements

"14/ $BFRI Biofrontera Ameluz for actinic keratosis sBCC acne 🔹Phase [--] enrollment complete 🔹superficial basal cell carcinoma 1-year FU done 🔹Cash: $1.8M (down from $5.9M) 🔹Patent protection extended to 2043"
X Link 2025-05-16T10:13Z [---] followers, [---] engagements

"15/🧬 $HCWB HCW Biologics Senescence-immunotherapies 🔹IND cleared for alopecia areata candidate 🔹$7M licensing deal pending 🔹Cash: $5M"
X Link 2025-05-16T10:13Z [---] followers, [---] engagements

"💊 Is the obesity drug race overcrowded 👉 Zealand Pharma ( $ZEAL ): dapiglutide (GLP1/GLP2) showed 11.6% weight loss in [--] weeks well tolerated few GI events [--] dropouts due to nausea/vomiting. 👉 Biomea Fusion ( $BMEA ): oral GLP1 agonist with strong weight loss in preclinical models. 🔑 What will truly set these drugs apart: ✔ Fewer GI side effects ✔ Oral delivery potential ✔ And above all LESS MUSCLE LOSS #biotech #obesity #GLP1 #GLP2 https://twitter.com/i/web/status/1935600134072463642 https://twitter.com/i/web/status/1935600134072463642"
X Link 2025-06-19T07:26Z [---] followers, [---] engagements

"https://www.globenewswire.com/news-release/2025/06/18/3101320/0/en/Biomea-Fusion-Reports-Preclinical-Data-for-BMF-650-a-Next-Generation-Oral-GLP-1-Receptor-Agonist-Candidate-Demonstrating-Robust-Weight-Loss-and-Appetite-Suppression-in-Obese-Non-Hu.html https://www.globenewswire.com/news-release/2025/06/18/3101731/0/en/Zealand-Pharma-announces-positive-topline-results-from-28-week-Phase-1b-trial-with-GLP-1-GLP-2-receptor-dual-agonist-dapiglutide.html"
X Link 2025-06-19T07:26Z [---] followers, [---] engagements

"💊 La carrera por las molculas contra la obesidad est saturada: 👉 Zealand Pharma $ZEAL : dapiglutide (GLP1/GLP2) muestra [---] % de peso en [--] semanas buena tolerabilidad pocos eventos GI [--] retiros por nuseas/vmitos. 👉 Biomea Fusion $BMEA : agonista oral GLP1 con fuerte prdida de peso en modelos preclnicos. 🔑 Lo que marcar la diferencia en estos frmacos para la obesidad: ✔ Menos nuseas y vmitos ✔ posibilidad oral ✔ Y sobre todo PERDER MENOS MSCULO #biotech #obesidad #GLP1 #GLP2 https://twitter.com/i/web/status/1935601103933952341 https://twitter.com/i/web/status/1935601103933952341"
X Link 2025-06-19T07:30Z [---] followers, [---] engagements

"$CCCC C4 Therapeutics: +7% Today💥 $100M market cap $200M in cash. They just achieved full remission in a myeloma patient. FDA talks could start soon is this stock undervalued $CCCC Analysis & other degraders here https://youtu.be/mbLqdIoAbGU https://youtu.be/mbLqdIoAbGU"
X Link 2025-06-24T15:57Z [---] followers, [----] engagements

"Kymera Therapeutics $KYMR anuncia oferta pblica de $250.8 M (5M acciones + 655K warrants) con opcin a 855K acciones adicionales 💵 Precio por accin: $44.00 📅 Cierre previsto: [--] de junio [----] 📌 Acciones en circulacin: 65M. (Diluidas totales estimadas 80M) 🎯 Objetivo: financiar su pipeline de degradadores orales para enfermedades inmunolgicas https://investors.kymeratx.com/static-files/427c6fbb-fa43-4150-9e28-e3d55b81617f https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-pricing-250-million-public"
X Link 2025-06-27T05:23Z [---] followers, [---] engagements

"Kymera Therapeutics $KYMR announces a $250.8M public offering (5M shares + 655K pre-funded warrants) with an option to purchase an additional 855K shares. 💵 Offering price: $44.00 📅 Expected closing date: June [--] [----] 📌 Shares outstanding: 65M (Est. fully diluted80M) 🎯 Use of proceeds: to fund its pipeline of oral protein degraders for immunological diseases. https://investors.kymeratx.com/static-files/427c6fbb-fa43-4150-9e28-e3d55b81617f https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-pricing-250-million-public"
X Link 2025-06-27T05:23Z [---] followers, [---] engagements

"Dyne Therapeutics $DYN $200 M public offering of 24M shares at $8.25 +option for up to 3M shares. 📊 Shares outstanding 113M (F. dil 133M) 💰 Cash $677.5M. Net Loss Q1 $115.4M (31 march 25) #Biotech #Finance #Stocks https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-reports-first-quarter-2025-financial-results https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-pricing-2000-million-public-offering"
X Link 2025-07-01T06:14Z [---] followers, [---] engagements

"$PROK ProKidney Phase [--] REGEN007 topline: 🏥 Group 1: kidney function stabilized (2 doses [--] in each kidney): +78% improvement in annual eGFR slope decline (from [---] preinjection to [---] mL/min/1.73m postinjection p0.001). 💉 Group [--] (1 injection + 2nd only if function worsened): +50% improvement but not statistically significant (p=0.085) suggests a doseresponse trend. ✅ No serious AEs related to rilparencel. 🔜 FDA Type B meeting this summer to confirm PROKs approach for Phase [--] PROACT1 targeting accelerated approval. 📅 Full data to be presented at ASN Kidney Week [----] (Nov 59)"
X Link 2025-07-09T07:01Z [---] followers, [---] engagements

"$PROK ProKidney resultados preliminares de Fase [--] REGEN007: 🏥 Grupo 1: la funcin renal estabilizada (2 dosis [--] en cada rin): +78 % de mejora en la pendiente anual de eGFR (de [--] antes de la inyeccin a [--] mL/min/173m tras la inyeccin p0001). 💉 Grupo [--] (1 inyeccin + segunda solo si empeora la funcin): +50 % de mejora pero sin significacin estadstica (p=0085); sugiere tendencia a respuesta por dosis. ✅ No se registraron efectos adversos graves relacionados con rilparencel. 🔜 Reunin FDA Tipo B este verano para confirmar el enfoque de PROK para Fase [--] PROACT1 con objetivo de aprobacin"
X Link 2025-07-09T07:05Z [---] followers, [---] engagements

"$PROK PROKIDNEY & FDA alignment on accelerated approval for rilparencel: ✅ FDA confirms eGFR slope is an acceptable surrogate endpoint in CKD + T2D 🧪 Ongoing Ph3 PROACT [--] for both accelerated and full approval [--] % of patients enrolled 📊 Data expected in Q2 [----] to support BLA #Biotech #FDA #CKD https://investors.prokidney.com/news-releases/news-release-details/prokidney-announces-alignment-fda-accelerated-approval-pathway https://investors.prokidney.com/news-releases/news-release-details/prokidney-announces-alignment-fda-accelerated-approval-pathway"
X Link 2025-07-15T14:55Z [---] followers, [---] engagements

"💥The GLP1 Battle Continues Today Hengrui. HRS9531 (GLP1/GIP): 1923% weight loss in Chinese Ph3 study PolyPid $PYPD. 60day GLP1 delivery platform with linear release 🤔 Too much competition among similar molecules #GLP1 #Obesity #biotech https://youtu.be/n-X0n7IPNzg https://youtu.be/n-X0n7IPNzg"
X Link 2025-07-15T15:17Z [---] followers, [---] engagements

"$AMRN Amarin Ingresos Q2: $72.7M (+8% YoY) Prdidas netas: $14.1M Cash: $298.7M 🌍 VAZKEPA (riesgo cardiovascular) crece en Europa 🤝 Nuevo acuerdo con Recordati 📉 Reestructura global para ahorrar $70M"
X Link 2025-07-31T09:47Z [---] followers, [--] engagements

"$IPN Ipsen H1 total ingresos: 1.82B Beneficio core neto: 508M (+27%) EPS: [----] IFRS EPS: [----] Cash: 487.6M 🚀 Suben gua 2025: Grecimiento de ventas +7% Margen operativo 32% 🧬 Pipeline activo: cabometyx (APROBADO) elafibranor tovorafenib fidrisertib IPN10200 https://twitter.com/i/web/status/1950855795723125116 https://twitter.com/i/web/status/1950855795723125116"
X Link 2025-07-31T09:47Z [---] followers, [--] engagements

"35 argenx Ingresos Q2: $967M (vs $489M in 2024) - Gastos Q2: $766M (vs $52M) Beneficio netoQ2: $245M (vs +$29M en 2024) Efectivo: +$362 M (vs $126M) VYVGART [-----] pacientes en tratamiento ARGX119 (ALS +SMA) datos ALS H1 [----] ARGX-109/213/121 datos en H2 [----] y H1 2026"
X Link 2025-07-31T09:47Z [---] followers, [--] engagements

"$PHARM Pharming Group Q2 Ingresos: $93.2M (+26%) Ingresos RUCONEST: $80.4M Ingresos Joenja: $12.8M Gasto operativo -$75.2M Beneficio operativo: +$10.8M Cash: $130.8M 📈 Suben gua 2025: $335350M"
X Link 2025-07-31T09:47Z [---] followers, [---] engagements

"$WVE Wave Life Sciences Q2 revenue: $8.7M (56% YoY) Net loss: $50.5M Cash: $208.5M (vs $302M in 2024) 🧬 Progress in WVE006 (AATD) and WVE007 (obesity): full dosing completed 📅 INLIGHT trial readout expected Q4 2025Q1 [----] ✅ Cash runway into 2027"
X Link 2025-07-31T09:51Z [---] followers, [---] engagements

"$AMRN Amarin Q2 revenue: $72.7M (+8% YoY) Net loss: $14.1M Cash: $298.7M 🌍 VAZKEPA (CV risk) growing in Europe 🤝 New distribution deal with Recordati 📉 Global restructuring underway to save $70M"
X Link 2025-07-31T09:51Z [---] followers, [--] engagements

"$IPN Ipsen H1 total revenue: 1.82B Core net profit: 508M (+27%) Cash: 487.6M 🚀 [----] guidance raised: Sales growth: +7% Core Op margin: 32% 🧬 Active pipeline: cabometyx (APPROVED) elafibranor tovorafenib fidrisertib IPN10200"
X Link 2025-07-31T09:51Z [---] followers, [---] engagements

"$ARGX argenx Q2 revenue: $967M (vs $489M in 2024) Q2 expenses: $766M (vs $52M) Net profit Q2: $245M (vs $29M in 2024) Operating cash flow: +$362M (vs $126M) VYVGART: [----] patients treated ARGX119 (ALS/SMA): ALS data in H1 [----] ARGX-109/213/121 readouts in H2 [----] & H1 2026"
X Link 2025-07-31T09:52Z [---] followers, [---] engagements

"$PHARM Pharming Group Q2 revenue: $93.2M (+26%) RUCONEST: $80.4M Joenja: $12.8M OpEx: $75.2M Operating profit: +$10.8M Cash: $130.8M 📈 [----] guidance raised: $335350M"
X Link 2025-07-31T09:52Z [---] followers, [---] engagements

"Annexon $ANNX Cash: $227M Net loss (Q2): $44.2M Runway: through Q426 Next: EU MarketingAA submission for ANX005 in Q126; Topline ARCHER II Data Expected in H2'26. Update on POC trial in cold agglutinin disease (CAD) anticipated by YE 25"
X Link 2025-08-15T09:26Z [---] followers, [---] engagements

"Pyxis Oncology $PYXS Cash: $90.4M Net loss Q2 $18.4M Runway: 2H26 Milestones: Ph1 monotherapy expansion of micvotabart pelidotin (MICVO) for metastatic head and neck squamous cell carcinoma (R/M HNSCC) preliminary data in H2'2025 - H1'2026 Ph1/2 MICVO + KEYTRUDA preliminary data in H2' [----] https://twitter.com/i/web/status/1956286357287977395 https://twitter.com/i/web/status/1956286357287977395"
X Link 2025-08-15T09:26Z [---] followers, [---] engagements

"Century Therapeutics $IPSC Cash: $158.5M Net loss (Q2): $32.5M Runway: Q427 Next: YE25 data updates for CNTY-101 (B-cell-mediated autoimmune diseases)"
X Link 2025-08-15T09:26Z [---] followers, [---] engagements

"MacroGenics $MGNX Cash: $176.5M Net Loss(Q2): $36.3M Runway: 1H27 Milestones: H225clinical update on LORIKEET trial (bispecific tetravalent PD-1 CTLA-4 DART)"
X Link 2025-08-15T09:26Z [---] followers, [---] engagements

"Lexeo Therapeutics $LXEO Cash: $152.5M Net loss (Q2): $26.1M Runway: [----] Next H225: interim clinical data of [--] patients in Ph I/II trial (HEROIC-PKP2) of LX2020 for PKP2-ACM (CARDIO)"
X Link 2025-08-15T09:26Z [---] followers, [---] engagements

"Werewolf Therapeutics $HOWL Cash: $77.6M Net loss (Q2): $18M Runway: Q426 Next: Q425: Tolerability response rate and durability data for WTX-124 (IL2+Pembro) Mono and Combo"
X Link 2025-08-15T09:26Z [---] followers, [---] engagements

"Shattuck Labs $STTK Cash: $50.5M (ex-PIPE) Net loss (Q2): $12.5M Runway: into [----] if $103M PIPE closes Next: Q325: IND clearance + first dosing (SL-325 IBD Bowel Disease)"
X Link 2025-08-15T09:26Z [---] followers, [---] engagements

"Abeona Therapeutics $ABEO Cash: $226M Net (Q2): $108M Runway: [--] years Next: U.S. launch on track and first ZEVASKYN patient treatment expected in 3Q 2025"
X Link 2025-08-15T09:26Z [---] followers, [---] engagements

"Candel Therapeutics $CADL Cash: $100.7M Net loss (Q2): $4.8M Runway: Q127 Next: Q425: CAN-3110 rHGG clinical and biomarker activity data; Q426: planned BLA for CAN-2409 (prostate)"
X Link 2025-08-15T09:26Z [---] followers, [--] engagements

"🧬 Another NASDAQ Biotech Watchlist: names with 1yr runway and H225 [---] catalysts Based on last weeks financials & business highlights Final wave of these names dropping in the next hoursAre these actually my holidays😂 Cash P&L Runway Next Milestones Dive 👇"
X Link 2025-08-18T10:43Z [---] followers, [---] engagements

"ORIC Pharmaceuticals $ORIC Cash: $327.7M (pro forma $436.4M) Net loss Q225: ($36.4M) Runway: 2H28 Next. 2H25: Ph1b data ORIC-944 and dose-opt (Q126) 2H25 ORIC-114 data for 1L EGFR exon [--] 2L EGFR exon [--] 2L+ HER2 exon [--] and 2L+ EGFR atypical data"
X Link 2025-08-18T10:43Z [---] followers, [---] engagements

"Mineralys Therapeutics $MLYS Cash: $324.9M Net loss Q2: $43.3M Runway: [----] Next: Q425 pre-NDA for lorundrostat; H126 Ph2 safety & afficacy data for obstructive sleep apnea (OSA) with lorundrostat"
X Link 2025-08-18T10:43Z [---] followers, [---] engagements

"Taysha Gene Therapies $TSHA Cash: $312.8M P&L: ($26.9M) Runway: [----] Next: Q425 start Ph3 pivotal REVEAL trial (Rett syndrome) + New supplemental clinical data from Part A of REVEAL Phase 1/2 trial"
X Link 2025-08-18T10:43Z [---] followers, [--] engagements

"Centessa Pharmaceuticals $CNTA Cash: $404.1M Net Loss Q2: $50.3M Runway: mid-2027 Next: Readouts 2025: Ph2 Narcolepsy and Hyperimnomnia (ORX750) Ph1 neurological and neurodegenerative disorders with data in acutely sleep-deprived healthy volunteers (ORX142)"
X Link 2025-08-18T10:43Z [---] followers, [---] engagements

"Korro Bio $KRRO Cash: $119.6M Net Loss Q2: $25.8M Runway: [----] Next: H225 Phase 1/2a Alpha-1 antitrypsin deficiency (AATD) KRRO-110 interim. Announce a development candidate for its rare metabolic disorder program by the end of [----]. Targeted to the liver using GalNAc to create de novo protein to have therapeutic effect. Progress partnership with Novo Nordisk in cardiometabolic diseases with high prevalence and substantial unmet clinical need"
X Link 2025-08-18T10:43Z [---] followers, [---] engagements

"Zenas BioPharma $ZBIO Cash: $274.9M Net Loss Q2: $52.2M Runway: Q426 Next: YE25 IgG4-Related Disease Ph3 INDIGO topline results; early Q425 Relapsing Multiple Sclerosis Ph2 12-wk"
X Link 2025-08-18T10:43Z [---] followers, [---] engagements

"ALX Oncology $ALXO Cash: $83.5M Net Loss Q2: $25.9M Runway: Q127 Next: Q425 ASPEN-06 CD47 Gastric Cancer updated data; 1H26 ALX2004 EGFR-expressing solid tumors Ph1 safety; Q3'26 ASPEN-BREAST"
X Link 2025-08-18T10:43Z [---] followers, [---] engagements

"ProKidney $PROK Cash: $294.7M Net Loss Q2: $37M Runway: mid-2027 Next: Nov [--] REGEN-007 FULL RESULTS at ASN. FDA Alignment Achieved. confirmed that the slope of estimated glomerular filtration rate (eGFR) in patients from the ongoing Phase [--] PROACT [--] study can serve as the surrogate endpoint and primary basis for a Biologics License Application (BLA) submission of rilparencel under the accelerated approval pathway. Topline data readout of eGFR slope as the surrogate endpoint to support an application for accelerated approval in Q2 [----] https://twitter.com/i/web/status/1957392833205211362"
X Link 2025-08-18T10:43Z [---] followers, [---] engagements

"Septerna $SEPN Cash: $379.2M Net Loss Q2: $24.8M Runway: [----] Next: Q325 start Ph1 (SEP-631 MRGPRX2 NAM) for the treatment of mast cell diseases. H126 start Ph1 (PTH1R) for day calcium control in hypoparathyroidism patients. Novo deal extends cash"
X Link 2025-08-19T08:51Z [---] followers, [---] engagements

"Lisata Therapeutics $LSTA Cash: $22M Net Loss Q2: $4.7M Runway: Q426 Next: Q425 BOLSTER: Phase 2a evaluating certepetide + SoC chemotherapy in cholangiocarcinoma (CCA). This year: ASCEND Ph2b final data in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Q126: iLSTA Ph1/2a (Gemcitabine/Nab-paclitaxel/Durvalumab + certepetide) in mPDAC"
X Link 2025-08-19T08:52Z [---] followers, [---] engagements

"PMV Pharmaceuticals $PMVP Cash: $148.3M Net Loss Q2: $21.2M Runway: YE26 Next: Sept [--] [----] Ph2 PYNNACLE interim for PC14586 a small molecule p53 reactivator designed to selectively bind to the pocket in the p53 Y220C mutant protein restoring the wild-type tumor-suppressor function. https://twitter.com/i/web/status/1957727242806575560 https://twitter.com/i/web/status/1957727242806575560"
X Link 2025-08-19T08:52Z [---] followers, [---] engagements

"MBX Biosciences $MBX Cash: $224.9M Net Loss: $19.4M Runway: mid-2027 Next: Topline results for the Phase [--] Avail trial of canvuparatide in hypoparathyroidism on track for Q3 [----] Imapextide (MBX 1416) Phase 2a trial initiation in patients with post-bariatric hypoglycemia anticipated in Q3 [----] MBX [----] Phase [--] trial initiation in obesity anticipated in Q3 [----] https://twitter.com/i/web/status/1957727244870095332 https://twitter.com/i/web/status/1957727244870095332"
X Link 2025-08-19T08:52Z [---] followers, [---] engagements

"C4 Therapeutics $CCCC Cash: $223M Net Loss Q2: $26M Runway: mid-2027 Next: Sept [--] Cemsidomide Phase [--] Data in Multiple Myeloma (July [--] Data Cutoff Ph1 ORR 40% at 75g Dose and 50%ORR at the 100g Dose). Registrational Development of Cemsidomide in Multiple Myeloma on Track to Initiate in Early [----] https://twitter.com/i/web/status/1957727246845698549 https://twitter.com/i/web/status/1957727246845698549"
X Link 2025-08-19T08:52Z [---] followers, [---] engagements

"Cullinan $CGEM Cash: $510M Net Loss: $70.1M Runway: [----] Next: Q425 SLE Ph1/2 initial safety Zipalertinib REZILIENT1 pivotal results shared in oral presentation at ASCO [----] and in Journal of Clinical Oncology; multiple new data sets across a range of disease settings to be shared at IASLC [----] WCLC and ESMO Congress [----] Q4 [----] Clinical data for CLN-049 (FLT3xCD3 bispecific T cell engager): Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)"
X Link 2025-08-19T08:52Z [---] followers, [---] engagements

"Rapport Therapeutics $RAPP Cash: $260.4M Net Loss Q2: $26.7M Runway: YE26 Next: RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025"
X Link 2025-08-19T08:52Z [---] followers, [---] engagements

"Sanofis Amlitelimab (anti-OX40L) $SANOFI $SNY hits all endpoints in the Ph3 COAST-1 trial for atopic dermatitis 🎯 Key points 👇 🔹 This OX40L antibody does not deplete T cells (see image) 🔹 Immunosuppression always raises concerns about pathogens but the risk/benefit balance matters 🔹 Mindblowing: more respiratory infections in placebo 🔹 Patient benefit: clear improvements on the vIGA-AD (Validated Investigator Global Assessment for Atopic Dermatitis) reaching 0/1 severity or a 2-point improvement (see table) https://twitter.com/i/web/status/1963518505573077420"
X Link 2025-09-04T08:24Z [---] followers, [---] engagements

"📢 $HCM HKEX: [--] HUTCHMED presentar nuevos datos clnicos en #ESMO2025 (October 17-21 Berln): - FRUSICA-2 (fruquintinib + sintilimab) en carcinoma renal avanzado - Anlisis de FRUSICA-1 en cncer de endometrio - Savolitinib en cncer de pulmn no microctico https://www.globenewswire.com/news-release/2025/10/02/3160056/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-the-ESMO-Congress-2025.html https://www.globenewswire.com/news-release/2025/10/02/3160056/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-the-ESMO-Congress-2025.html"
X Link 2025-10-02T08:46Z [---] followers, [---] engagements

"📢 $HCM HKEX: [--] HUTCHMED will present new clinical data at #ESMO2025 (October 17-21): - FRUSICA-2 (fruquintinib + sintilimab) in advanced renal cell carcinoma - Analyses of FRUSICA-1 in endometrial cancer - Savolitinib in non-small cell lung cancer https://www.globenewswire.com/news-release/2025/10/02/3160056/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-the-ESMO-Congress-2025.html https://www.globenewswire.com/news-release/2025/10/02/3160056/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-the-ESMO-Congress-2025.html"
X Link 2025-10-02T08:46Z [---] followers, [---] engagements

"⚡ Noticias de acciones biotecnologicas. 23_10_25 Ventyx ( $VTYX): +82% Resultados en Fase [--] (Obesidad/CV). Tango ( $TNGX): Cae -8% PERO recibe $225M de institucionales. Oportunidad Enterabio ( $ENTX): Fase [--] con aumentos en densidad sea. AGENDA: Datos de Arvinas ( $ARVN) y BioCryst ( $BCRX) en Oct/Nov. Y ms: $VTYX $TNGX $PHVS $ENTX $ARVN $BCRX $CRNX $GTBP $MAIA $INBS $TLX $PCRX $GRCE $GBIO Mira el resumen rpido👇 https://www.youtube.com/shorts/0Q-B5UzBV4c https://www.youtube.com/shorts/0Q-B5UzBV4c"
X Link 2025-10-23T16:02Z [---] followers, [---] engagements

"⚡ Biotech Stock News. 10.23.25 Ventyx ( $VTYX): +82% Phase [--] Results (Obesity/CV). Tango ( $TNGX): Down -8% BUT receives $225M from institutional investors. Opportunity Entera Bio ( $ENTX): Phase [--] with increases in bone density. AGENDA: Data from Arvinas ( $ARVN) and BioCryst ($BCRX) in Oct/Nov. And more: $VTYX $TNGX $PHVS $ENTX $ARVN $BCRX $CRNX $GTBP $MAIA $INBS $TLX $PCRX $GRCE $GBIO Watch the quick summary 👇 https://www.youtube.com/shorts/hMf6PUMO7Uw https://www.youtube.com/shorts/hMf6PUMO7Uw"
X Link 2025-10-23T16:02Z [---] followers, [---] engagements

"Immutep ( $IMMP ) Quarterly Activities Report (Q1 FY26). TACTI-004 (Keynote-F91) Phase [--] (NSCLC) now [---] sites active across [--] countries. Completion in the Q1 [----]. Positive FDA feedback for late-stage development in H&N Cancer PD-L1 low expression Phase II/III Trial in Metastatic Breast Cancer update will be provided Dec [----]. Cash $109.85 M runway through end-2026. https://www.globenewswire.com/news-release/2025/10/29/3176384/0/en/Immutep-Quarterly-Activities-Report-Q1-FY26.html"
X Link 2025-10-30T16:49Z [---] followers, [---] engagements

"United Therapeutics ( $UTHR ) Revenue $799.5M (+7 % YoY). Net income $338 M (+10 %); Cash $4.3 B R&D pipeline expanding (xenotransplant and organs). https://www.businesswire.com/news/home/20251029382455/en/United-Therapeutics-Corporation-Reports-Record-Third-Quarter-2025-Financial-Results https://www.businesswire.com/news/home/20251029382455/en/United-Therapeutics-Corporation-Reports-Record-Third-Quarter-2025-Financial-Results"
X Link 2025-10-30T16:49Z [---] followers, [--] engagements

"Phathom Pharmaceuticals ( $PHAT ) Q3 [----] net revenues: $49.5 M (+25% QoQ). Filled prescriptions: [------] in Q3; [------] cumulative. Net loss Q3 $30M. Cash & equivalents: $135.2 M Updated FY [----] revenue guidance: $170$175 M; expects operating profitability in [----] Key commercial/product highlight: VOQUEZNA launch gaining momentum realigned sales force toward gastroenterology specialists. https://www.globenewswire.com/news-release/2025/10/30/3177229/0/en/Phathom-Pharmaceuticals-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update.html"
X Link 2025-10-31T15:53Z [---] followers, [--] engagements

"argenx ( $ARGX ) 💰 Cash & current financial assets: $4.3 billion 💵 Revenue: $1.15 billion (Q3 2025) vs $589 M (Q3 2024) +95%. 🧩 Pipeline Highlights: VYVGART franchise growth; sBLA filing for seronegative gMG subtypes by YE 25; five registrational readouts expected in 2026; multiple early-stage candidates targeting immunology. 🎯 Next Milestones: sBLA submission for VYVGART in seronegative gMG subtypes (MuSK+ LRP4+ triple negative) by end [----]. Topline results ADAPT-OCULUS (ocular MG) in 1H 26; ADVANCE-NEXT (primary ITP) in 2H [--]. Registrational CMS study for ARGX-119 starting 2026; Phase 1"
X Link 2025-10-31T15:53Z [---] followers, [--] engagements

"$STIM (Neuronetics Inc.) Cash: $34.5M (also raised $7.8M via ATM + secured $10M debt tranche) Q3 Net loss: $9.4M Pipeline/updates: Greenbrook clinics revenue up +25% (US $21.8M) driving growth; CEO transition planned for June [--] [----] Next catalysts: Q4 revenue outlook $40M-$43M; full-year guidance $147M-$150M"
X Link 2025-11-05T15:44Z [---] followers, [---] engagements

"$PRLD (Prelude Therapeutics Inc.) only strategic business update Cash: $52M + upfront $60M deal with Incyte Corporation runway into [----] possibly Q3 [----] if option exercised results to be released Nov [--] [----] Pipeline/updates: Strategic pivot: prioritizing mutant-selective JAK2V617F inhibitor & KAT6A degrader programs; pausing SMARCA2 program Next catalysts: Q3 results Nov 12; early clinical initiation of KAT6A degrader mid-2026; option deal milestones from Incyte https://twitter.com/i/web/status/1986097391993332059 https://twitter.com/i/web/status/1986097391993332059"
X Link 2025-11-05T15:44Z [---] followers, [---] engagements

"$NVCT (Nuvectis Pharma) Cash: $35.4M Runway: Expected into Q3 [----]. Q3 Net loss: $7.5M. Pipeline/updates: Initiated Phase 1b for NXP900 monotherapy; completed Phase 1a dose-escalation with robust pharmacodynamics; DDI study done. Stock Titan Next catalysts: Early Phase 1b monotherapy readouts; combination dosing initiation by year-end. https://twitter.com/i/web/status/1986097404693631352 https://twitter.com/i/web/status/1986097404693631352"
X Link 2025-11-05T15:44Z [---] followers, [---] engagements

"$BCRX (BioCryst) Cash: $269.4M. Q3 Net income: $12.9M. YTD: $18M. Next catalysts: 💊 PDUFA for ORLADEYO granules (HAE kids 212) set for Dec [--] [----] could be the first oral prophylactic therapy for pediatric HAE. 🤝 Astria aquisition ( $ATXS ); adds navenibart a long-acting anti-kallikrein mAb (Ph3). Deal expected Q1 [----]. 🧫 BCX17725 (KLK5 inhibitor Netherton) & avoralstat (DME) in Ph1 data expected by Q1 [----] and EOY [----]. https://twitter.com/i/web/status/1986097410628587804 https://twitter.com/i/web/status/1986097410628587804"
X Link 2025-11-05T15:44Z [---] followers, [---] engagements

"$TGTX (TG Therapeutics) Cash: $178.3M. Q3 Net income $390.9M. YTD$424M FY25 guide: Raised to $600M total revenue; U.S. BRIUMVI $585M. Pipeline/updates: Completed patient enrollment into the randomized Phase [--] pivotal program to evaluate a consolidated Day [--] and Day [--] dosing regimen for IV BRIUMVI in the ongoing ENHANCE trial Next catalysts: Completed $100M share buyback (3.5M shares @ avg $28.55). Board approved a new $100M repurchase program. https://twitter.com/i/web/status/1986097412947988784 https://twitter.com/i/web/status/1986097412947988784"
X Link 2025-11-05T15:44Z [---] followers, [---] engagements

"$PYXS (Pyxis Oncology) Cash: $77.7M Runway: into 2H [----]. Q3 Net loss $22M. ($21.1M in Q3 2024) Next catalysts: Preliminary MICVO (micvotabart pelidotin) Phase [--] R/M HNSCC data expected in Q425"
X Link 2025-11-05T15:44Z [---] followers, [---] engagements

"$DCTH (Delcath Systems) Cash : $88.9 million Q3 Net income : $0.8 million (vs. $1.9 million income in Q3 2024) Revenue: $20.6 million in Q3 [----] vs. $11.2 million in Q3 [----] (+84%) Pipeline/updates: First patient dosed in global Phase [--] HEPZATO KIT combo trial for liver-dominant mCRC; investigator-initiated Phase [--] CHOPIN trial in metastatic uveal melanoma presented improved 1-yr PFS. Next catalysts: Top-line data expected [----] from the Phase [--] HEPZATO combo trial; expansion of treatment centers; commercialization scaling of HEPZATO & CHEMOSAT"
X Link 2025-11-05T15:44Z [---] followers, [---] engagements

"$BMEA Biomea Fusion Cash: $47.0M. Runway Q1 [----] Q3 net: -$16.4M vs -$32.8M [----] Next milestones: Icovamenib (menin) Ph2 start Q425 (trial COVALENT-212)and Q1 2026(trial COVALENT-211). BMF-650 wt-loss Ph1 28d data 1H26"
X Link 2025-11-06T15:47Z [---] followers, [---] engagements

"$CRVS Corvus Pharmaceuticals Cash: $65.7M Q3 net loss: $10.2M vs $40.2M (Q324) Pipeline Milestones: Lead asset Soquelitinib (ITK inhibitor) for atopic dermatitis (Phase [--] extension cohort [--] completed; data expected Jan 2026) & Phase [--] AD trial on track early Q1 [----]. Phase [--] registrational in relapsed/refractory PTCL enrolling. https://www.globenewswire.com/news-release/2025/11/04/3180825/0/en/Corvus-Pharmaceuticals-Provides-Business-Update-and-Reports-Third-Quarter-2025-Financial-Results.html"
X Link 2025-11-06T15:47Z [---] followers, [---] engagements

"$MLTX MoonLake Immunotherapeutics Cash/runway: $380M. Runway H2 [----] Net loss: $70M. Pipeline: Confirmed a Type B meeting with the FDA on December [--] [----] to support a BLA of SLK in HS. Other clinical trials of SLK expected data releases from the Phase [--] S-OLARIS trial in Axial Spondyloarthritis (axSpA) and the Phase [--] IZAR trials in Psoriatic Arthritis (PsA) 👉 https://www.globenewswire.com/news-release/2025/11/05/3181261/0/en/MoonLake-Immunotherapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Announces-New-Data-from-Clinical-Trials-of-its-Nanobody-Sonelokimab.html"
X Link 2025-11-06T15:47Z [---] followers, [---] engagements

"$SION Sionna Therapeutics Cash: $325.0M runway into [----]. Q3 net loss: $20.3M vs $25.4M in Q324. Pipeline: Initiated Phase 2a proof-of-concept trial of SION-719 (NBD1 stabilizer) in CF as add-on to standard of care; also initiated Phase [--] trial of SION-451 in dual combinations. Next milestone: Topline data from both trials expected mid-2026. 👉 https://www.globenewswire.com/news-release/2025/11/05/3181269/0/en/Sionna-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html https://twitter.com/i/web/status/1986460420853338476"
X Link 2025-11-06T15:47Z [---] followers, [--] engagements

"$LRMR Larimar Therapeutics Cash: $175.4M. runway into Q4 [----]. Q3 net loss: $47.7M vs $15.5M in Q324. Pipeline: Lead asset nomlabofusp (for Friedreichs ataxia) BLA submission targeted Q2 [----] U.S. launch early [----]. 👉 https://www.globenewswire.com/news-release/2025/11/05/3181277/0/en/Larimar-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html https://www.globenewswire.com/news-release/2025/11/05/3181277/0/en/Larimar-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html"
X Link 2025-11-06T15:47Z [---] followers, [---] engagements

"$FHTX Foghorn Therapeutics Cash: $180.3 M Runway: Into [----]. Q3 net loss: $15.8 M vs $19.1 M in Q324. Pipeline: FHD-909 (SMARCA2 inhibitor) in Phase 1; collaborating with Eli Lilly and Company on degraders (CBP EP300 ARID1B) in oncology. Next milestone: IND-readiness for select CBP degrader in 2026; in vivo PoC for ARID1B degrader in [----]. 👉 https://www.globenewswire.com/news-release/2025/11/05/3181279/0/en/Foghorn-Therapeutics-Provides-Third-Quarter-2025-Financial-and-Corporate-Update.html"
X Link 2025-11-06T15:47Z [---] followers, [---] engagements

"$ARVN Arvinas Cash: $787M Runway: Extended to H2 [----] Q3 net loss: $35.1 M vs $49.2M Q3 [----] Pipeline: partnership with Pfizer Inc. for vepdegestrant. Next milestones: Phase 1b start for ARV-102 in H1 [----]. Vepdegestrant PDUFA action date of June [--] [----]. ARV-806: Share initial clinical data in patients with solid tumors harboring KRAS G12D mutations (2026). 👉 https://www.globenewswire.com/news-release/2025/11/05/3181298/0/en/Arvinas-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html"
X Link 2025-11-06T15:47Z [---] followers, [---] engagements

"$AQST Aquestive Therapeutics Cash: $129.1M. Estimated cash runway and sufficiency to support the launch of Anaphylm if approved by the FDA Q325: Net loss $15.4M (vs 11.5M in Q3 2024) Next milestones: PDUFA DATE JAN [--] [----] for Anaphylm. The first and only oral medication for the rescue treatment of severe allergic reactions including anaphylaxis"
X Link 2025-11-07T12:14Z [---] followers, [---] engagements

"$DYN Dyne Therapeutics Cash: $792M Runway: into Q327 Q325: Net loss $108M (vs 97M Q3 2024) Next milestones: Topline data for DYNE-251 in DMD on track for December [----] to support potential submission for U.S. Accelerated Approval in Q2 2026"
X Link 2025-11-07T12:14Z [---] followers, [---] engagements

"$PRQR ProQR Cash: 106.9M Runway: mid-27 Q325: Net loss 11M Next milestones: Phase [--] study of AX-0810 in healthy volunteers initial safety tolerability and PK data from Cohort [--] expected by year-end. target engagement data from all cohorts in H1 2026"
X Link 2025-11-07T12:14Z [---] followers, [---] engagements

"$NEUM Neumora Therapeutics Cash: $171M Runway [----] Q325: Net loss $56.8M (vs [----] Q3 2024) Next milestones: END 2025: Data from Phase 1b study of NMRA-511 in Alzheimers disease agitation Q1 [----] highly brain-penetrant oral NLRP3 inhibitor"
X Link 2025-11-07T12:14Z [---] followers, [---] engagements

"$BDTX Black Diamond Therapeutics Cash: $135.5M Runway: into Q4-2027 Q325: Net loss $8.5M (vs $15.6M Q3 2024) Next milestones: ORR and preliminary duration of treatment data for the Phase [--] trial of silevertinib in 1L patients with non-classical EGFRm NSCLC on track for this quarter. + FDA feedback on a potential registrational path in frontline EGFR mutant NSCLC in the first half of 2026"
X Link 2025-11-07T12:14Z [---] followers, [---] engagements

"$MBX MBX Biosciences Cash: $391M Runway : [----] Q325: Net loss $21M (vs $18M) Next milestones: CanvuparatideQ1 2026: End of Phase [--] meeting and EMA Scientific Advice Q2 2026: Presentation of Phase [--] results at a medical meeting Q2 2026: Phase [--] one-year open label extension study data Q3 2026: Phase [--] canvuparatide HP trial initiation MBX 4291Q4 2026: Results from 12-week multiple ascending dose portion of Phase [--] trial of MBX [----] for the treatment of obesity ImapextideQ2 2026: Phase 2a STEADI trial results of imapextide for the treatment of post-bariatric hypoglycemia (PBH)"
X Link 2025-11-07T12:14Z [---] followers, [---] engagements

"Analizo [--] empresas biotecnolgicas del Nasdaq con caja hasta [----] y catalizadores importantes previstos para [--------]. Tickers incluidos: $ALT $CART $DYNE $CRNX $ETON $DNLI $RZLT $LXEO $UPB $SYRE $RYTM $ACIU $NMB $BBIO $NVCR https://youtu.be/Ss9_iV8PGxw https://youtu.be/Ss9_iV8PGxw"
X Link 2025-11-17T15:21Z [---] followers, [---] engagements

"03_12_25 Biotech Stock News. Daily Recap. English $CAPR $PHVS $BCRX $OKYO $BDTX $RLMD $CLNN $BNTX $CVAC"
X Link 2025-12-03T17:54Z [---] followers, [---] engagements

"04_12_25 Biotech Stock News. Daily Recap. English $PLRX $PSTV $QURE $CBIO $SNTI $PPCB $SNY $ENLV"
X Link 2025-12-04T15:31Z [---] followers, [---] engagements

"10_12_25 Biotech Stock News. Daily Recap. English $SAGE $AMRX $FULC $KYMR $TERN $DNLI Sagimet Amneal Fulcrum Kymera Terns Denali"
X Link 2025-12-10T15:15Z [---] followers, [---] engagements

"10_12_25 Noticias de acciones biotecnolgicas. Resumen diario. #Espaol #Shorts #Biotech $AMRX $FULC $KYMR $TERN $DNLI Sagimet Amneal Fulcrum Kymera Terns Denali"
X Link 2025-12-10T15:15Z [---] followers, [---] engagements

"15_DECEMBER_25 🗞🧬 Biotech Stock News. Daily Recap. English Kyverna $KYTX Rezolute $RZLT Milestone $MIST Adaptive $ADPT Pfizer $PFE Fortress $FBIO Profusa $PFSA Dyadic $DYAI FibroGen $FGEN Sanofi $SAN Sanofi $SNY"
X Link 2025-12-15T15:35Z [---] followers, [---] engagements

"@YYDSxjm I have concerns about $IOVAs next catalyst (IOV-4001). How are PD-1 knockout TILs expected to behave in anti-PD1 refractory patients It seems redundant. Although they are likely more potent the tumor may have developed other evasion mechanisms"
X Link 2026-01-24T09:44Z [---] followers, [---] engagements

"@Pharmdca I have concerns about $IOVAs next catalyst (IOV-4001). How are PD-1 knockout TILs expected to behave in anti-PD1 refractory patients It seems redundant. Although they are likely more potent the tumor may have developed other evasion mechanisms"
X Link 2026-01-24T09:45Z [---] followers, [---] engagements

"29_01_26 Noticias de acciones biotecnolgicas . Resumen diario. $APRE $IMMP $SER $GUTS $PFSA #Espaol #Shorts #diario $XBI https://www.youtube.com/shorts/rfNZi5I00GY https://www.youtube.com/shorts/rfNZi5I00GY"
X Link 2026-01-29T16:21Z [---] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing